Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs QUALCOMM, Inc. (QCOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs QUALCOMM, Inc. — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.9 (market cap $8.87B), while QUALCOMM, Inc. trades at $171.56 (market cap $188.86B). The key difference: QUALCOMM, Inc. is far larger — about 21.3× Kymera Therapeutics Inc. Common Stock's market cap, and QUALCOMM, Inc. pays a 2.08% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and QUALCOMM, Inc. for 87 Days on average.
| KYMR | QCOM | |
|---|---|---|
Market Cap | $8.87B | $188.86B |
Volume | 779,107 | 12,280,716 |
Sector | Health | Technology |
52-Week High | $127.31 | $251.10 |
52-Week Low | $55.80 | $124.07 |
Typical Hold Time | 0 Days | 87 Days |
Enterprise Value | $8.26B | $195.82B |
Dividend Yield | — | 2.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Qualcomm (QCOM) trades at $174.43, down 0.61% today, with a bearish technical signal despite recent AI-driven optimism. The company reported mixed Q2 2026 earnings, missing EPS estimates at $2.21 versus $2.23 expected, but maintains strong profitability with 54.23% gross margins and 21.01% net income margin. Recent news highlights a transformative $60 billion Amazon AI partnership, boosting data center ambitions beyond its core handset business.
QCOM's valuation appears reasonable with a P/E of 20.21, trading below the analyst consensus price target of $204.48. Key opportunities include AI data center growth and automotive expansion, while risks involve smartphone dependency and competitive pressures. Wall Street sentiment is mixed with 43.48% buy ratings, but the stock offers potential upside if AI bets materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About QUALCOMM, Inc.
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G and 4G networks. The firm is a leader in 5G network technology as well. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones and chips into automotive and Internet of Things markets.
Read more on QCOM →
